Guyer William: insider trades.
Guyer William reported 10 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($4.1M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 5
- Companies
- 1
- Name as filed
- Guyer William
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Corcept Therapeutics Inc (CORT) | Officer · Chief Development Officer | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-01 | Corcept Therapeutics Inc | A | 164 | $113.38 | 4,149 | Form 4 |
| 2026-09-01 | Corcept Therapeutics Inc | A | 164 | $0 | 4,313 | Form 4 |
| 2026-08-10 | Corcept Therapeutics Inc | S | 11,530 | $113.18 | 8,755 | Form 4 |
| 2026-08-10 | Corcept Therapeutics Inc | S | 4,770 | $114.04 | 3,985 | Form 4 |
| 2026-08-10 | Corcept Therapeutics Inc | M | 16,300 | $21.65 | 20,285 | Form 4 |
| 2026-08-04 | Corcept Therapeutics Inc | S | 3,700 | $113.12 | 3,985 | Form 4 |
| 2026-08-04 | Corcept Therapeutics Inc | M | 3,700 | $21.65 | 7,685 | Form 4 |
| 2026-07-07 | Corcept Therapeutics Inc | M | 20,000 | $21.65 | 23,985 | Form 4 |
| 2026-07-07 | Corcept Therapeutics Inc | S | 19,048 | $93.11 | 4,937 | Form 4 |
| 2026-07-07 | Corcept Therapeutics Inc | S | 952 | $93.54 | 3,985 | Form 4 |
Questions
What stock did Guyer William buy or sell?
Guyer William reported 10 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($4.1M), across 1 company.
Is Guyer William the same person as other filers with this name?
This page covers SEC CIK 1879013 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/guyer-william-1879013.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.